<SEC-DOCUMENT>0001104659-23-073567.txt : 20230622
<SEC-HEADER>0001104659-23-073567.hdr.sgml : 20230622
<ACCEPTANCE-DATETIME>20230622084008
ACCESSION NUMBER:		0001104659-23-073567
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230622
FILED AS OF DATE:		20230622
DATE AS OF CHANGE:		20230622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		231031558

	BUSINESS ADDRESS:	
		STREET 1:		55TH-56TH FLOOR, NEW BUND CENTER
		STREET 2:		555 WEST HAIYANG ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200124
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		55TH-56TH FLOOR, NEW BUND CENTER
		STREET 2:		555 WEST HAIYANG ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200124
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2319318d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the month of </FONT>June&nbsp;2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commission
File Number: </FONT>001-39173</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>I-MAB</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">55th Floor, New Bund Center, 555 West Haiyang
Road, Pudong District</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shanghai, 200124</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">People&rsquo;s Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F
</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Form&nbsp;40-F
<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit&nbsp;No.</U></B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; font-size: 10pt"><A HREF="tm2319318d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt"><A HREF="tm2319318d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">I-MAB</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
<TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
<TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 43%">/s/ Richard Yeh</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Yeh</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer and Interim Chief Financial Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June&nbsp;22, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2319318d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2319318d1_ex99-1img001.jpg" ALT="" STYLE="height: 89px; width: 240px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>I-Mab Announces the
Appointment of Raj Kannan as CEO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GAITHERSBURG,
MD. and SHANGHAI, CHINA, June&nbsp;22, 2023 </B></FONT>&mdash; I-Mab (&ldquo;I-Mab&rdquo; or the &ldquo;Company&rdquo;) (Nasdaq: IMAB),
a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies,
today announced the appointment of Mr.&nbsp;Raj Kannan as the Company&rsquo;s new Chief Executive Officer and a member of the board of
directors effective June&nbsp;22, 2023. This appointment serves as a significant step towards further realizing I-Mab&rsquo;s mission
of delivering transformative therapies to patients worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raj
Kannan has over 30 years of industry experience in creating and developing global specialty medicine franchises as a biotech CEO. Mr.&nbsp;Kannan
has successfully led blockbuster product launches across several therapeutic areas including oncology both in the U.S. and globally.
More recently, as the Chief Executive Officer of Aerie Pharmaceuticals, and before that of Chiasma Pharmaceuticals, he delivered significant
value to shareholders exiting both companies successfully while increasing the potential reach of approved and candidate medicines. Mr.&nbsp;Kannan&rsquo;s
bio can be found at <U>https://www.i-mabbiopharma.com/leadership/</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I am very pleased to welcome Mr.&nbsp;Raj
Kannan on board. Raj joins the Company at a critical juncture to strengthen its strategic position as a U.S.-based global company. Raj
is a distinguished leader with the global experience and vision to drive sustainable growth and realize the full potential of our differentiated
oncology portfolio as we move into our next phase of growth and innovation,&rdquo; said Dr.&nbsp;Jingwu Zang, Founder and Chairman of
I-Mab. &ldquo;I would also like to thank Dr.&nbsp;Andrew Zhu, who had served as acting Chief Executive Officer of the Company since September&nbsp;2022.
Andrew will continue to lead the Company&rsquo;s R&amp;D as President of I-Mab and serve as a member of the board of directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;It is an exciting time to be joining I-Mab
with the Company&rsquo;s advanced and differentiated clinical assets generating promising clinical data,&rdquo; said Mr.&nbsp;Kannan.
&ldquo;I look forward to working with Dr.&nbsp;Zang and the talented team at I-Mab to further advance the robust pipeline to deliver on
the full potential of the portfolio globally.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About I-Mab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">I-Mab (Nasdaq:
IMAB) is a dynamic, global biotech company focused on discovery, development and soon, commercialization of novel or highly differentiated
biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company</FONT>&rsquo;s mission is to bring transformational
medicines to patients around the world through innovation. I-Mab&rsquo;s innovative pipeline of more than 10 clinical and pre-clinical
stage drug candidates is driven by the Company&rsquo;s Fast-to-Proof-of-Concept and Fast-to-Market development strategies through internal
R&amp;D and global partnerships and commercial partnerships. I-Mab has established its global footprint in Shanghai, Beijing, Hangzhou,
Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit <U>http://www.i-mabbiopharma.com
</U>and follow I-Mab on <U>LinkedIn</U>, <U>Twitter,</U> and <U>WeChat</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2319318d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>I-Mab Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This announcement contains forward-looking statements.
These statements are made under the &quot;safe harbor&quot; provisions of the U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as &quot;will,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;future,&quot;
&quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;confident&quot; and similar statements. I-Mab
may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the &quot;SEC&quot;),
in its annual report to shareholders, in press releases and other written materials and oral statements made by its officers, directors
or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations,
are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual
results to differ materially from those contained in any forward-looking statement, including but not limited to the following: I-Mab's
ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support
further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory
approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability
to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's limited operating history and I-Mab's
ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; I-Mab&rsquo;s
strategies, plans, objectives and goals and I-Mab&rsquo;s ability to successfully implement these strategies, plans, objectives and goals,
as well as those risks more fully discussed in the &quot;Risk Factors&quot; section in I-Mab's most recent annual report on Form&nbsp;20-F,
as well as discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All
forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>I-Mab Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 58%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Richard Yeh</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Operating Officer, interim Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>IR@i-mabbiopharma.com</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 42%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gigi Feng<BR>
    Chief Communications Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>PR@i-mabbiopharma.com</U></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2319318d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2319318d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: /,# 2(  A$! Q$!_\0
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M+E/O+ZCU%=V$QZJR=*II+\SUZ-932N;E%%%>H= 4444 %%%% !1110 4444
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MPHHHJ2C \;L5\#ZT5.#]DD'YC%?-5O&*^E?''_(CZS_UZO\ RKYPMA7KY?\
M"_4\7,OB7H=5I%SYEJ(F/S1C ]Q6WIUA+J5_%:0CYI#C/H.YKE+)S%(KJ>17
MK/PZAAD@NKS*F7<(P.ZCJ?S_ *5Z%>K[*DY'CT,/[:NH=&=C86,.G64=K H"
M(,?4^IJU117S+;;NS[&,5%66P53U+3;35;-[6\A66)NQZCW'I5RL3Q)JRZ?8
M-&C?Z1*-J#N!W-85ZL*5-SGLA2M;4\T>QATZ22VMV+PH[!&/4C)I*L,-PP:K
MD$'!KX3VCFVWN>?**CL;_@V0IXAC4?QHRG\L_P!*](KS7P>I/B. _P!U7/\
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M/TY_*N,C9'\#^&FCC\L'4K?*[L_-YIW'/N<G\:FO)WM)M0\*@E#?7"_9"O\
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
